細胞名稱

人多發(fā)性骨髓瘤細胞OPM2

貨物編碼

BFN60808728

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研     2類

培養(yǎng)體系

DMEM高糖+10%FBS+1%三抗

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人多發(fā)性骨髓瘤細胞OPM2取自56歲女性供體。該細胞源于DSMZ。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Characteristics: Produces Ig lambda.

Doubling time: 30-36 hours (PubMed=3926660); 50 hours (PubMed=25984343); ~50-60 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Derived from sampling site: Peripheral blood.

基因突變

Heterozygous for CDKN2A p.His83Tyr (c.247C>T) (Cosmic-CLP).

Heterozygous for FGFR3 p.Lys650Glu (c.1948A>G) (PubMed=11157491; Cosmic-CLP).

Heterozygous for SMAD2 p.Leu87Arg (c.260T>G) (Cosmic-CLP).

Homozygous for TP53 p.Arg175His (c.524G>A) (PubMed=21173094; Cosmic-CLP).

HLA信息

Class I

HLA-A        A*24

HLA-B        B*07,15

HLA-C        C*04,07

STR信息

Amelogenin        X

CSF1PO        12,13

D3S1358        15,18

D5S818        13

D7S820        12

D8S1179        10,13

D13S317        11

D16S539        9,13

D18S51        13,14

D21S11        30,33.2

FGA        20,21

Penta D        9

Penta E        12,21

TH01        6,7

TPOX        8

vWA        14,17

參考文獻

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=30545397; DOI=10.1186/s13045-018-0679-0

Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S., Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M., Pellat-Deceunynck C.

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

J. Hematol. Oncol. 11:137-137(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402(2020)